Bionano Genomics announces publication of study using OGM

SAN DIEGO, September 21, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) as we speak introduced the publication of a research that makes use of OGM to find coding balanced chromosomal rearrangements (BCRs) present in individuals who have skilled recurrent being pregnant loss. (RPL). In contrast with standard cytogenetic strategies, OGM was profitable in figuring out the reciprocal coding translocation in all samples, which improved the success price find pathogenic variants of coding BCRs and simplified the invention course of.

The researchers analyzed samples from 11 {couples} who had handled RPL, had a historical past of getting a child or fetus with a chromosome loss or achieve, or had a historical past of infertility to find out the usefulness of OGM for detecting encoded BCRs, which may considerably improve the danger of delivering irregular offspring with Congenital malformations or miscarriages for service {couples}. The OGM confirmed 100% concordance with the outcomes of fluorescence in situ hybridization (FISH) and sequencing analyzes and revealed further advanced rearrangement occasions corresponding to inverted aberrations, additional bettering potential genetic interpretation. The research authors highlighted the challenges related to utilizing conventional strategies and cited the fast and sturdy OGM detection of high-resolution encoded BCRs as proof for his or her potential utility as a first-line methodology in routine scientific genetic testing.

Eric Holmlin, Ph.D., President and CEO of Bionano, commented, “This research demonstrates OGM help in an space that we imagine could also be very useful for individuals with infertility and being pregnant loss. We’re happy to see the researchers recommending OGM as an preliminary technique to change conventional strategies, a few of which have been It has been round for 50 years.”

This submit could be discovered right here: https://jmg.bmj.com/content material/early/2022/06/15/jmedgenet-2022-108553

Concerning the Bionano . genome

Bionano Genomics is an organization that gives genome evaluation options that may allow researchers and clinicians to uncover solutions to difficult questions in biology and drugs. The corporate’s mission is to vary the way in which the world sees the genome by means of OGM options, diagnostic companies and software program. The corporate delivers OGM options for functions throughout primary, translational and scientific analysis. Via the Lineagen enterprise, the corporate additionally gives diagnostic exams for sufferers with scientific displays suitable with autism spectrum dysfunction and different neurodevelopmental disabilities. Via its BioDiscovery enterprise, the corporate additionally presents an industry-leading, platform-less software program answer, which integrates next-generation sequencing and microarray information designed to supply evaluation, visualization, interpretation, and reporting of copy quantity variants, single nucleotide variants, and absences of heterozygosity throughout the genome in a single view. unified. For extra data go to www.bionanogenomics.comAnd the www.lineagen.com or www.biodiscovery.com

Ahead-looking statements for Bionano Genomics

This press launch incorporates forward-looking statements throughout the that means of the Personal Securities Litigation Reform Act of 1995. Phrases corresponding to “might,” “may,” “imagine,” and related expressions (in addition to different phrases or phrases that confer with future occasions, circumstances or situations) They convey uncertainty about future occasions or outcomes and are supposed to establish these forward-looking statements. Ahead-looking statements embrace statements concerning our intentions, beliefs, expectations, expectations, analyzes or present expectations referring to, amongst different issues, the flexibility and usefulness of the OGM to detect cryptographic BCRs. Every of those forward-looking statements includes dangers and uncertainties. Precise outcomes or developments may differ materially from these projected or implied in these forward-looking statements. Elements that will trigger this distinction embrace dangers and uncertainties related to: the influence of the COVID-19 pandemic on our enterprise and the worldwide economic system; normal market situations; Modifications within the aggressive panorama and introduction of aggressive applied sciences or enhancements to current applied sciences; The outcomes of the potential research fail to help these described within the paper referenced on this press launch; OGM fails to detect encoded BCRs; adjustments in our strategic and enterprise plans; Our capability to acquire ample funding to fund our strategic plans and advertising and marketing efforts; The flexibility of medical and analysis establishments to acquire funding to help the adoption or continued use of our applied sciences; and the dangers and uncertainties related to our enterprise and monetary situation on the whole, together with these described in our filings with the Securities and Trade Fee, together with, with out limitation, our annual report on Type 10-Okay for the 12 months ended December 31, 2021 and in different filings which we later filed with the Securities and Trade Fee. All forward-looking statements on this press launch communicate solely as of the date they have been made and are primarily based on administration’s assumptions and estimates as of that date. We undertake no obligation to publicly replace any forward-looking statements, whether or not because of the receipt of latest data, the incidence of future occasions, or in any other case.

Contacts
Firm contact:
Eric Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Level
+1 (858) 366-3243
amy@juniper-point.com